Immunocore Holdings plc
IMCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune. The company carries a $1.60B market cap, placing it firmly in the small-cap category. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Market Cap
$1.60B
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
-40.31
EPS (TTM)
$-0.36
EPS (Fwd)
$-0.77
ROE
-4.5%
ROA
-0.2%
Cash
$880.2M
Total Debt
$435.0M
Free CF
$35.6M
52W Change
-7.4%
Annual Financials
Cash vs Debt
Where IMCR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IMCR finished 5.21% below its 150-day moving average ($31.48) and 6.22% below its 200-day moving average ($31.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMCR overbought or oversold?
At the October 20, 2026 close, IMCR's RSI(14) was 42.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Immunocore Holdings plc holds $880.2M in cash against $435.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $35.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -4.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $174.4M (2022) to $400.0M (2025), reflecting a 129% increase over the period.
With cash comfortably exceeding debt, IMCR has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immunocore Holdings plc's trajectory.